AnaptysBio Inc.
AnaptysBio Inc. is listed today as AnaptysBio, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2015 | $41 M | No. 2 | $10 to $50 million | equity | SEC | |
| Oct 2011 | $8 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company AnaptysBio, Inc., its revenue in fiscal 2025 came from these business segments: Royalty Management $234.60 million (100%).
Annual report (SEC XBRL) · Dec 2025
AnaptysBio Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2015).
SEC Form D · Jul 2015
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jul 2015
Products and services#
No products or services of AnaptysBio Inc. are on record.
Investors#
12 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Carol Giltner Gallagher | Person | not stated | not stated | Held Series C and D preferred stock, director (Form 3, 2017) | SEC Form 3 |
| FHM VII, L.L.C. | Other | not stated | not stated | Held Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| FHM VII, L.P. | Fund or asset manager | not stated | not stated | Held Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| FHM V, LLC | Other | not stated | not stated | Held Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| FHM V, LP | Fund or asset manager | not stated | not stated | Held Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Frazier Healthcare VII-A, L.P. | Fund or asset manager | not stated | not stated | Held Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Frazier Healthcare VII, L.P. | Fund or asset manager | not stated | not stated | Held Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Frazier Healthcare V, LP | Fund or asset manager | not stated | not stated | Held Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Hamza Suria | Person | not stated | not stated | Held Series C, C-1 and D preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Marco Londei | Person | not stated | not stated | Held Series D preferred stock (Form 3, 2017) | SEC Form 3 |
| Nicholas Lydon | Person | not stated | not stated | Held Series B, C and D preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series B, C, C-1 and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 19 investors.
Largest shareholders today
Institutions holding AnaptysBio, Inc. shares, as of Sep 30, 2026.
- EcoR1 Capital, LLC$396 M26.36%
- BlackRock, Inc.$95 M6.33%
- Tang Capital Management LLC$74 M4.93%
- State Street Corp$58 M3.83%
- Vanguard Capital Management LLC$46 M3.04%
- Goldman Sachs Group Inc$43 M2.84%
- Sanofi$41 M2.75%
- D. E. Shaw & Co., Inc.$41 M2.74%
- Millennium Management LLC$39 M2.62%
- 683 Capital Management, LLC$37 M2.48%
- Citadel Advisors LLC$33 M2.18%
- Geode Capital Management, LLC$32 M2.14%
- Palo Alto Investors LP$30 M1.99%
- Pertento Partners LLP$27 M1.82%
- Arrowstreet Capital, Limited Partnership$25 M1.66%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Hamza Suria | Executive officer | Jul 2015 |
| Marco Londei | Executive officer | Jul 2015 |
| Robert Hoffman | Executive officer | Jul 2015 |
| Hamza N. Suria | Executive officer | Oct 2011 |
| Carol Gallagher | Director | Jul 2015 |
| Hamza Suria | Director | Jul 2015 |
| Hollings Renton | Director | Jul 2015 |
| James Topper | Director | Jul 2015 |
| John Schmid | Director | Jul 2015 |
| Nicholas Lydon | Director | Jul 2015 |
| Tiba Aynechi | Director | Jul 2015 |
| Carol N. Gallagher | Director | Oct 2011 |
| Heath Lukatch | Director | Oct 2011 |
| J. Leighton Read | Director | Oct 2011 |
| James N. Topper | Director | Oct 2011 |
| Kevin Kinsella | Director | Oct 2011 |
| Nick Lydon | Director | Oct 2011 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.